S Abdelwahab1, A Azmy, H Abdel-Aziz, H Salim, A Mahmoud. 1. Department of Clinical Oncology, Ain Shams University, 17 Abbas Akkad street extension, Nasr City, Cairo, 11371, Egypt. sherifok69@hotmail.com
Abstract
PURPOSE: This study was conducted to test the efficacy and toxicity of cetuximab and irinotecan as a biweekly regimen in treatment of elderly patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Forty-nine elderly patients (≥65 years) with mCRC who progressed after at least one previous line of treatment were enrolled into this study from May 2008 to January 2011. All recruited patients received cetuximab 500 mg/m(2) and irinotecan 180 mg/m(2) every 2 weeks. RESULTS: Thirty-seven patients (76 %) were men, and 76 % of patients had colonic cancer in origin. Median age was 69 years. Median overall survival time was 7 months, and median progression-free survival was 4 months. Grade 3-4 skin rash occurred in 20 % of patients, grade 3-4 diarrhea in 18 % of patients, and neutropenia in 28 % of patients. CONCLUSION: Cetuximab combined with irinotecan when administered biweekly is safe and effective for treatment of pretreated elderly patients with mCRC.
PURPOSE: This study was conducted to test the efficacy and toxicity of cetuximab and irinotecan as a biweekly regimen in treatment of elderly patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Forty-nine elderly patients (≥65 years) with mCRC who progressed after at least one previous line of treatment were enrolled into this study from May 2008 to January 2011. All recruited patients received cetuximab 500 mg/m(2) and irinotecan 180 mg/m(2) every 2 weeks. RESULTS: Thirty-seven patients (76 %) were men, and 76 % of patients had colonic cancer in origin. Median age was 69 years. Median overall survival time was 7 months, and median progression-free survival was 4 months. Grade 3-4 skin rash occurred in 20 % of patients, grade 3-4 diarrhea in 18 % of patients, and neutropenia in 28 % of patients. CONCLUSION:Cetuximab combined with irinotecan when administered biweekly is safe and effective for treatment of pretreated elderly patients with mCRC.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: J Tabernero; F Ciardiello; F Rivera; E Rodriguez-Braun; F J Ramos; E Martinelli; M E Vega-Villegas; S Roselló; S Liebscher; O Kisker; T Macarulla; J Baselga; A Cervantes Journal: Ann Oncol Date: 2009-11-25 Impact factor: 32.976
Authors: B Vincenzi; D Santini; C Rabitti; R Coppola; B Beomonte Zobel; L Trodella; G Tonini Journal: Br J Cancer Date: 2006-03-27 Impact factor: 7.640
Authors: P Martín-Martorell; S Roselló; E Rodríguez-Braun; I Chirivella; A Bosch; A Cervantes Journal: Br J Cancer Date: 2008-08-05 Impact factor: 7.640
Authors: Nadine J McCleary; William S Harmsen; Ellana Haakenstad; James M Cleary; Jeffrey A Meyerhardt; John Zalcberg; Richard Adams; Axel Grothey; Alberto F Sobrero; Eric Van Cutsem; Richard M Goldberg; Marc Peeters; Josep Tabernero; Matt Seymour; Leonard B Saltz; Bruce J Giantonio; Dirk Arnold; Mace L Rothenberg; Miriam Koopman; Hans-Joachim Schmoll; Henry C Pitot; Paulo M Hoff; Niall Tebbutt; Gianluca Masi; John Souglakos; Carsten Bokemeyer; Volker Heinemann; Takayuki Yoshino; Benoist Chibaudel; Aimery deGramont; Qian Shi; Stuart M Lichtman Journal: JNCI Cancer Spectr Date: 2022-03-02
Authors: Shamik Chakraborty; Christopher G Filippi; Tamika Wong; Ashley Ray; Sherese Fralin; A John Tsiouris; Bidyut Praminick; Alexis Demopoulos; Heather J McCrea; Imithri Bodhinayake; Rafael Ortiz; David J Langer; John A Boockvar Journal: J Neurooncol Date: 2016-03-05 Impact factor: 4.130
Authors: Efrat Dotan; Karthik Devarajan; A James D'Silva; Andrew Beck; Dwight D Kloth; Steven J Cohen; Crystal Denlinger Journal: Clin Colorectal Cancer Date: 2014-06-26 Impact factor: 4.481
Authors: E Martinelli; C Cardone; T Troiani; N Normanno; S Pisconti; V Sforza; A R Bordonaro; A M Rachiglio; M Lambiase; T P Latiano; G Modoni; S Cordio; F Giuliani; M Biglietto; V Montesarchio; C Barone; G Tonini; S Cinieri; A Febbraro; D Rizzi; F De Vita; M Orditura; G Colucci; E Maiello; F Ciardiello Journal: ESMO Open Date: 2017-02-20
Authors: J Feliu; A Salud; M J Safont; C García-Girón; J Aparicio; R Vera; O Serra; E Casado; M Jorge; P Escudero; C Bosch; U Bohn; R Pérez-Carrión; A Carmona; V Martínez-Marín; J Maurel Journal: Br J Cancer Date: 2014-06-19 Impact factor: 7.640